Cardiology consensus - Company finances
|
EUR
|
2023
From: 2023-08-09
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|
|
Financial data
|
|||
| Sales revenue | 35,612 | 68,226 | 112,391 |
| Profit before tax | 35,527 | 61,427 | 37,566 |
| Net profit | 35,527 | 58,381 | 35,245 |
| Equity | 35,577 | 93,958 | 129,203 |
| Liabilities | 200 | 3,306 | 236,980 |
| Non-current assets | 0 | 2,719 | 304,955 |
| Current assets | 35,777 | 94,545 | 61,228 |
| Total assets | 35,777 | 97,264 | 366,183 |
|
Taxes paid
|
|||
| STI taxes | - | 127 | 3,046 |
|
Financial indicators
|
|||
| Revenue change y/y | - | +91.6% | +64.7% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 99.3% | 60.0% | 9.6% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 99.9% | 62.1% | 27.3% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 99.8% | 85.6% | 31.4% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 99.8% | 90.0% | 33.4% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.0 | 0.0 | 1.8 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Cardiology consensus - Social security debts
The company had no debts to Sodra
Cardiology consensus - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Cardiology consensus, MB (code 306376610) is a Lithuanian small partnership engaged in research and development in medical sciences. In 2025, the company generated revenue of €112.4K and net profit of €35.2K, with a profit margin of 31.4%. Revenue continued to expand strongly, rising from €35.6K in 2023 to €68.2K in 2024 and then to the latest level in 2025; this reflects 64.7% year-on-year growth and 215.6% growth over two years. Net profit also remained positive throughout the period, although it moved from €35.5K in 2023 and €58.4K in 2024 to €35.2K in 2025. The 2023 figures cover a 144-day period, while 2024 and 2025 reflect full-year results. At the end of 2025, total assets stood at €366.2K, equity at €129.2K and liabilities at €237.0K. Long-term assets reached €305.0K, and short-term assets €61.2K. Key ratios for 2025 indicate ROE of 27.3%, ROA of 9.6%, debt-to-equity of 1.83 and asset turnover of 0.31x.